3,329.30
+1.41%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sanofi India
Its shares trade on NSE under the ticker SANOFI.NS. It has been listed since 28 November 1994. In the fiscal year to 31 December 2025, it reported revenue of ₹18.37bn and net income of ₹3.27bn. At that date it held total assets of ₹12.55bn and shareholders' equity of ₹7.49bn.
Sanofi India Ltd. engages in the manufacturing and distribution of pharmaceutical drugs. The company is headquartered in Mumbai, Maharashtra. The Company’s products are offered across four categories, which includes pharmaceuticals, consumer health care, vaccines and specialty care. The company offers medicines for therapy areas, such as diabetes (both insulins and orals), cardiology, thrombosis, anti-infectives, central nervous system, allergy and vitamins, and minerals and supplements. Its pharmaceutical products include Adenocor, Lantus, Aldurazyme, AllStar, Amaryl MP, Amaryl M, Apidra, Arava, Aubagio and Thymoglobuline. Its specialty care products include Myozyme, Cerezyme, Aldurazyme, Aubagio and Jevtana. Its consumer healthcare products include Allegra, Allegra nasal, Avil, Combiflam, Combiflam Plus and Lactacyd. Its vaccines products include Adacel, Avaxim 80U/160U, FluQuadri, Hexaxim, Menactra, Tetraxim, Vaxigrip, Stamaril, Shanvac-B and ShanTT.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 28 Nov 1994
- Employees
- 2,505
- Website
- sanofiindialtd.com ↗
Leadership
Pay as last reported
- Mr. Aditya NarayanIndependent Non-Executive Chairman of the Board₹3.5m
- Mr. Surendra AgarwallChief Financial Officer, Whole-Time Director, since 2024
- Mr. Rodolfo HroszManaging Director, Whole Time Director, since 2022₹36.4m
- Mr. Himanshu BakshiManaging Director
- Ms. Renee AmonkarWhole Time Director, since 2023₹1.9m
- Mr. N BabuSales & Customer Engagement Head - Diabetes
- Mr. Bratin BagSenior Director - Ethics and Business Integrity, South Asia
- Ms. Surabhi KaulDirector - People and Culture, India
- Ms. Yasmin ShenoySenior Director - Regulatory Affairs
- Mr. Linumon ThomasDigital Leader, India
- Mr. Nakul VermaSenior Director - Public Affairs
- Ms. Radhika ShahCompany Secretary, Head of Legal
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 68
- Environment
- 99
- Social
- 87
- Governance
- 18
- Direct emissions (scope 1)
- 486.63 t
- Energy emissions (scope 2)
- 8,476.77 t
- Value chain emissions (scope 3)
- 25,731 t
- Women in the workforce
- 20%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sanofi India Ltd possesses several strengths that contribute to its success in the market. These include:
Weaknesses
- Despite its strengths, Sanofi India Ltd also faces certain weaknesses that can hinder its growth and competitiveness. These include:
Opportunities
- Sanofi India Ltd has several opportunities to explore and capitalize on in the ever-evolving pharmaceutical industry. These include:
Threats
- Sanofi India Ltd faces various threats that could potentially disrupt its operations and profitability. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.